𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐧𝐠 𝐨𝐧 2024 : 𝐀 𝐘𝐞𝐚𝐫 𝐨𝐟 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 As we bid farewell to 2024, we are proud to look back on a year filled with significant strides toward our vision of a healthier and sustainable world. The progress we’ve made this year has not only shaped our future but has also brought us closer to making a meaningful impact on diabetes care globally. 𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐁𝐚𝐫𝐫𝐢𝐞𝐫𝐬 𝐢𝐧 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐂𝐚𝐫𝐞 One of our proudest achievements was the launch of first Biosimilar Insulin Aspart in collaboration with USV in India which was fully commercialized this year, marking a landmark moment as the country’s first biosimilar insulin analogue was approved. By improving access to cutting-edge insulin analogues, we’re transforming the lives of patients in underserved communities, but we’re also setting standards for diabetes care. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 On the international front, we took a significant step toward advancing healthcare access by submitting a Letter of Intent (LOI) for our insulin analogue to the European Medicines Agency (EMA). This submission underscores our unwavering commitment to ensuring that patients around the world have access to affordable, high-quality therapies. 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐝 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐢𝐧 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 R&D has been at the heart of everything we do. We continued advancing our research and development efforts, with ongoing trials for two additional insulin analogues, and the progression of two complex analogues,GLP-1's and a diabetic foot ulcer (DFU) product. These developments are a testament to our commitment to delivering affordable solutions for managing diabetes and improving patient outcomes. 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐂𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 To meet the growing demand for our products, we launched capacity expansion projects. Construction is underway at our existing Puducherry facility, and our greenfield projects in Sanand (India) and Muscat (Oman) are progressing rapidly. These expansions will add 500 kg of drug substance, and 45 million cartridge fills and finishes, increasing our ability to manufacture and supply high-quality biosimilars. We expect the Puducherry expansion to be completed by 2025, and the Sanand and Muscat facilities by mid-2026, with commercial production to follow shortly thereafter. 𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐀𝐡𝐞𝐚𝐝: 𝐎𝐮𝐫 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐚 𝐁𝐞𝐭𝐭𝐞𝐫 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰 The achievements of 2024 are a powerful reminder of the impact that science, collaboration, and innovation can have on improving global healthcare. As we step into 2025, we remain dedicated to driving progress and creating lasting solutions that transform lives and contribute to a healthier future for all. #Innovation #Healthcare #Biosimilars #DiabetesCare
About us
Biogenomics is a science-driven, vertically integrated pharmaceutical company specializing in treatments for diabetes and oncology. Backed by Oman Investment Authority and guided by a team of distinguished scientists, business leaders, and experts in molecular biology, microbiology, and protein engineering, Biogenomics has in a short span of time has developed a wide portfolio of biosimilars and biotech products. As an industry pioneer, Biogenomics became the first company in India to successfully launch a biosimilar of Insulin Aspart. With a robust pipeline, the company has several additional products awaiting approval. Committed to enhancing patient outcomes globally, Biogenomics has an active clinical development program focused on advancing chemical entities and biologics for the treatment of diabetes, cancer, and other critical therapeutic areas. As a young, fast-growing biopharmaceutical firm, Biogenomics is on a path to delivering excellence in healthcare. Our mission is to enrich lives by providing high-quality, affordable drugs, ensuring patient access to expensive specialty pharmaceuticals and biologic treatments. With two new additional manufacturing facilities coming up in India and Oman, Biogenomics is poised for significant global expansion. Beginning filings in 2025, the company plans to extend its reach into North America, Europe, and other key markets, further solidifying its international presence.
- Website
-
http://www.biogenomics.co.in
External link for BioGenomics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Thane, Maharashtra
- Type
- Public Company
- Specialties
- Biosimilars, Biologics , Insulins, Pharmaceuticals, Diabetes , Obesity , Diabetic foot ulcer, mAbs, Oncology , and Enzymes
Locations
-
Get directions
Thane
Thane, Maharashtra 400610, IN
-
Get directions
Ahmedabad
Ahmedabad, Gujarat, IN
-
Get directions
Manapet road
Pondicherry, IN
-
Get directions
Muscat
Muscat, OM
Employees at BioGenomics
-
Shambhu Chaturvedi
-
Namit Rustagi
Chief M&A and Group Legal Counsel - Diversified Group in Energy, manufacturing, Services, Aviation, Yacht construction, Real Estate, Mining and…
-
SELAMBARASAN T.G
Downstream - executive at BioGenomics Ltd.
-
Imran Shaikh
Expert & Investment Director, Healthcare and Diversification - Oman Investment Authority
Updates
-
Happy New Year!! #pharma #biopharma #biotechnology #newyearwishes
-
-
We are hiring!! #pharma #biopharma #biotechnology #businessdevelopment #recruitment #LATAM
-
-
BioGenomics reposted this
At BioGenomics, we believe in sustainable Employee Wellbeing Initiatives. Thank you all for your wholehearted participation during Chair Yoga session by our colleague, Sanjay Patil. #pharma #biopharma #biotechnology #health #employeewellbeing #empoloyeewellness #employeengagement
-
-
At BioGenomics, we believe in sustainable Employee Wellbeing Initiatives. Thank you all for your wholehearted participation during Chair Yoga session by our colleague, Sanjay Patil. #pharma #biopharma #biotechnology #health #employeewellbeing #empoloyeewellness #employeengagement
-
-
BioGenomics reposted this
On World Diabetes Day, we stand with millions managing diabetes worldwide. At Biogenomics we are committed to advancing affordable, high-quality diabetes solutions to improve lives. Together, let’s create a healthier future. #WorldDiabetesDay #DiabetesLife
-
-
On World Diabetes Day, we stand with millions managing diabetes worldwide. At Biogenomics we are committed to advancing affordable, high-quality diabetes solutions to improve lives. Together, let’s create a healthier future. #WorldDiabetesDay #DiabetesLife
-
-
Happy Diwali!! #pharma #biopharma #biotechnology #diwali #employeengagement
-
Happy Dussehra!! #pharma #biopharma #biotechnology #dussehra
-
-
Happy Gandhi Jayanti!! #pharma #biopharma #biotechnology
-